Rigel Pharmaceuticals (RIGL) Q4 2024 earnings summary

Executive summary

• Achieved record net product sales of $145 million in 2024, up 39% year-over-year, driven by Tavalisse, Rezlidhia, and Gavreto, with total revenue of $179.3 million.

• Reached profitability and positive cash flow for the first time, with full-year net income of $17.5 million, compared to a net loss of $25.1 million in 2023.

• Expanded international presence with regulatory approvals for Tavalisse in Mexico and Korea, and new licensing agreements for Rezlidhia in Asia and Latin America.

• Advanced pipeline with progress in R289 (Fast Track and Orphan Drug designations) and new studies for olutasidenib.

• Increased cash balances by over $20 million, ending 2024 with $77.3 million in cash, cash equivalents, and short-term investments.

Financial highlights

• Q4 2024 net product sales reached $46.5 million, up 58% year-over-year, with Tavalisse $31 million, Rezlidhia $7.4 million, and Gavreto $8.1 million.

• Full-year 2024 total revenues were $179.3 million, up from $116.9 million in 2023.

• Q4 contract revenues from collaborations totaled $11.1 million, including $4 million from Dr. Reddy's upfront fee.

• Year-end cash, cash equivalents, and short-term investments were $77.3 million, up from $56.9 million at end of 2023.

• Full-year 2024 cost of product sales: $18.6 million; total cost and expenses: $155.1 million (vs. $137.4 million in 2023).

Outlook and guidance

• 2025 revenue guidance: $200–$210 million total, including $185–$192 million in net product sales and $15–$18 million in contract revenues.

• Anticipates approximately 28–32% year-over-year growth in net product sales for 2025.

• Expects to maintain profitability and positive net income in 2025 while funding new and existing clinical programs.

• Plans to complete R289 phase 1b dose escalation and initiate dose expansion; phase 2 study for olutasidenib in recurrent glioma to begin by year-end.